These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24665658)

  • 1. [Use of antiplatelet agents in patients with chronic kidney disease: what is the evidence?].
    Gabrielli A; Bouatou Y; Saudan P
    Rev Med Suisse; 2014 Feb; 10(419):487-90, 492. PubMed ID: 24665658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet agents make a comeback in ST-elevation myocardial infarction.
    Wiviott SD; de Lemos JA
    Am Heart J; 2007 Oct; 154(4):603-6. PubMed ID: 17892976
    [No Abstract]   [Full Text] [Related]  

  • 3. Approaching an age of reason with antiplatelet therapy.
    Ajani AE; Lefkovits J
    Lancet; 2008 Apr; 371(9621):1315-6. PubMed ID: 18424309
    [No Abstract]   [Full Text] [Related]  

  • 4. Ticagrelor--is there need for a new player in the antiplatelet-therapy field?
    Schömig A
    N Engl J Med; 2009 Sep; 361(11):1108-11. PubMed ID: 19717845
    [No Abstract]   [Full Text] [Related]  

  • 5. New antiplatelet agents for cardiovascular disease.
    Chua D; Nishi C
    CMAJ; 2013 Nov; 185(16):1405-11. PubMed ID: 24016786
    [No Abstract]   [Full Text] [Related]  

  • 6. "Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient?
    Kern MJ
    Catheter Cardiovasc Interv; 2012 Feb; 79(2):255-62. PubMed ID: 22271555
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of ticagrelor in clopidogrel nonresponders: resistance is futile?
    Tapp L; Shantsila E; Lip GY
    Circulation; 2010 Mar; 121(10):1169-71. PubMed ID: 20194888
    [No Abstract]   [Full Text] [Related]  

  • 8. Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient).
    Wynn RL
    Gen Dent; 2010; 58(1):7-9. PubMed ID: 20129886
    [No Abstract]   [Full Text] [Related]  

  • 9. Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
    Norgard NB; Dinicolantonio JJ
    Postgrad Med; 2013 Jul; 125(4):91-102. PubMed ID: 23933898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Test before you stop.
    Kumar A; Roberts DH
    Arch Surg; 2009 Aug; 144(8):787; author reply 787. PubMed ID: 19687387
    [No Abstract]   [Full Text] [Related]  

  • 11. Ticagrelor in ACS: redefining a new standard of care?
    Stone GW
    Lancet; 2010 Jan; 375(9711):263-5. PubMed ID: 20079529
    [No Abstract]   [Full Text] [Related]  

  • 12. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
    Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM;
    Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Novel agents in antiplatelet therapy].
    Ağırbaşlı M; Güvenç H; Cinçin A
    Turk Kardiyol Dern Ars; 2010 Jul; 38(5):369-78. PubMed ID: 21200111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.
    Orban M; Riegger J; Joner M; Tada T; Okrojek R; Hausleiter J; Kastrati A; Massberg S; Sibbing D
    Platelets; 2012; 23(5):395-8. PubMed ID: 22671583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
    Clemmensen P; Dridi NP; Holmvang L
    Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive antiplatelet therapy for reduction of ischaemic events.
    Ramaraj R
    Lancet; 2008 Aug; 372(9638):531; author reply 532. PubMed ID: 18707975
    [No Abstract]   [Full Text] [Related]  

  • 18. Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease.
    Desai RJ; Spoendlin J; Mogun H; Gagne JJ
    Pharmacotherapy; 2017 Oct; 37(10):1322-1327. PubMed ID: 28833345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prasugrel: Clinical development and therapeutic application.
    Guerra DR; Tcheng JE
    Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet therapy beyond 2012: role of personalized medicine.
    Tantry US; Budaj A; Gurbel PA
    Pol Arch Med Wewn; 2012; 122(6):298-305. PubMed ID: 22751292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.